Paroxysmal nocturnal hemoglobinuria: Clinical presentation, diagnosis and treatment
Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2009, Vol 26, Issue 4
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder of hematopoietic stem cell characterized by the presence of intravascular hemolysis, marrow failure, nocturnal hemoglobinuria, thrombosis and rarely leukemia transformation. PNH is related to a somatic mutation in the phosphatidylinositol glycan class A (PIG-A), X-linked gene, responsible for a deficiency in glycosylphosphatidylinositol-anchored proteins (GPI-APs). The lack of GPI-APs complement regulatory proteins CD55 and CD59 leads to hemolysis. The diagnosis is based on flow cytometry, which allowed direct quantification of the GPI-AP-deficient cells. The clinical polymorphism of PNH has been recognized by four presentations; one form, predominantly hemolytic without overt marrow failure, referred to classic PNH, one with marrow failure that is often described as the aplastic anemia PNH syndrome (AA-PNH), a very mild disease with almost no symptoms (mini-PNH), and the hypoplastic form of PNH. Thromboses remain a major life threatening complication affecting outcomes in all disease subcategories. Thrombotic events are characterized by involvement of unusual sites (hepatic, mesenteric, cerebral, dermal veins). Treatment of PNH is mainly symptomatic. Allogeneic bone marrow transplantation is the only curative option in case of severe complications during the course of the diseases. A new targeted treatment strategy is the inhibition of the terminal complement cascade with the monoclonal antibody eculizumab which is a C5-inhibitor humanized monoclonal antibody. In classic PNH recent studies have shown that eculizumab is efficient to reduce complement mediated intravascular hemolysis, reduce the need for transfusions, improve the quality of life in patients with PNH and reduce the risk for thromboembolic complications, which are the main cause of mortality in PNH. Concerning the AA-PNH syndrome, allogeneic bone marrow transplantation is the reference treatment in young patients with a sibling donor. Immunosuppressive therapy remains an important treatment modality in this subcategory for patients without a donor or ineligible for BMT. Recurrent thrombotic events remains even now associated with bad prognosis, whatever the form of the disease.
Authors and Affiliations
J. MELETIS, A. SARANTOPOULOS, E. TERPOS
Keywords
Related Articles
- EP ID EP139407
- DOI -
- Views 100
- Downloads 0
An unusual case of co-existence of Hookworm with HIV infection in a patient in Greece
The case is described of a 32 year-old HIV positive female patient who complained of gastrointestinal disorders for 3 months (diarrhea, abdominal pain, lack of appetite, vomiting) and had low blood Fe levels. The antiv...
Mesenchymal tumors in the tubular gastrointestinal track
No abstract available
Job satisfaction among substance abuse treatment employees
Job satisfaction is the evaluation of an individual of his(her) professional and work context. It is related to the emotional and psychological well-being of employees and to the organizational functioning in the workpla...
Canine and feline influenza: Possible new emerging zoonoses?
No abstract available
The hepatopulmonary syndrome: Current trends
Lung complications may occur as a result of hepatic disease from any cause and they represent a highly heterogeneous group of conditions. The hepatopulmonary syndrome (HPS) is characterized as the triad of liver disease,...